{
    "hands_on_practices": [
        {
            "introduction": "One of the first critical hurdles in translational medicine is determining a safe starting dose for first-in-human clinical trials. This practice guides you through the fundamental process of interspecies dose scaling, using preclinical toxicology data to inform the safety parameters of your initial Target Product Profile (TPP) . Mastering this calculation is essential for bridging the gap between non-clinical safety studies and the design of a Phase 1 protocol.",
            "id": "5006100",
            "problem": "A translational medicine team is drafting a Target Product Profile (TPP) for a first-in-human study and needs to propose a conservative starting human dose based on preclinical toxicology. In a good laboratory practice dog study using Beagle dogs with mean body mass $10$ kg, the No-Observed-Adverse-Effect Level (NOAEL) was determined to be $10$ mg/kg. Assume the pharmacokinetic driver of systemic exposure scales allometrically with body mass $W$ with exponent $0.75$, consistent with the empirical observation that physiological clearance and related processes scale as $Y \\propto W^{0.75}$. The team will apply a safety factor of $10$ to the human-equivalent dose to derive the proposed starting dose. The intended study population is healthy adults with a representative body mass of $70$ kg.\n\nUsing only these premises and starting from the allometric scaling law $Y \\propto W^{0.75}$ and the definition of the safety factor, derive the appropriate interspecies scaling relationship for dose normalized by body mass and compute the absolute starting human dose for a $70$ kg adult. Express the final dose in mg and round your answer to three significant figures.",
            "solution": "The problem requires the calculation of a conservative starting dose for a first-in-human clinical trial based on preclinical toxicology data. The process involves interspecies dose scaling using an allometric relationship and the application of a safety factor. The solution will proceed by first deriving the general formula for scaling a dose per unit body mass between species, and then applying this formula with the given parameters to compute the final absolute dose.\n\nThe fundamental principle for interspecies scaling is to achieve equivalent systemic exposure of the drug, which is often quantified by the Area Under the plasma concentration-time Curve (AUC). The AUC is determined by the total dose administered and the drug's clearance (CL) from the body:\n$$\n\\text{AUC} = \\frac{\\text{Dose}_{\\text{total}}}{\\text{CL}}\n$$\nTo achieve equivalent exposure in the human as observed at the No-Observed-Adverse-Effect Level (NOAEL) dose in the animal model (dog), we set their AUCs to be equal:\n$$\n\\text{AUC}_{\\text{human}} = \\text{AUC}_{\\text{dog}}\n$$\n$$\n\\frac{\\text{Dose}_{\\text{total, human}}}{\\text{CL}_{\\text{human}}} = \\frac{\\text{Dose}_{\\text{total, dog}}}{\\text{CL}_{\\text{dog}}}\n$$\nThe problem states that physiological processes like clearance scale allometrically with body mass ($W$) according to the relationship $Y \\propto W^{b}$, with the exponent given as $b = 0.75$. Therefore, we can write the clearance for each species as $\\text{CL} = k W^{b}$, where $k$ is a proportionality constant assumed to be the same across species.\n$$\n\\text{CL}_{\\text{human}} = k W_{\\text{human}}^{0.75} \\quad \\text{and} \\quad \\text{CL}_{\\text{dog}} = k W_{\\text{dog}}^{0.75}\n$$\nSubstituting these expressions into the AUC equivalency equation:\n$$\n\\frac{\\text{Dose}_{\\text{total, human}}}{k W_{\\text{human}}^{0.75}} = \\frac{\\text{Dose}_{\\text{total, dog}}}{k W_{\\text{dog}}^{0.75}}\n$$\nThe constant $k$ cancels, and we can solve for the total human dose that is equivalent to the total dog dose:\n$$\n\\text{Dose}_{\\text{total, human}} = \\text{Dose}_{\\text{total, dog}} \\left( \\frac{W_{\\text{human}}}{W_{\\text{dog}}} \\right)^{0.75}\n$$\nThe dose is typically given in units of mass of drug per unit body mass (e.g., mg/kg). Let $D$ represent this normalized dose. The total dose is thus the product of the normalized dose and the body mass, $\\text{Dose}_{\\text{total}} = D \\times W$. We can substitute this into the equation above:\n$$\nD_{\\text{human}} \\times W_{\\text{human}} = (D_{\\text{dog}} \\times W_{\\text{dog}}) \\left( \\frac{W_{\\text{human}}}{W_{\\text{dog}}} \\right)^{0.75}\n$$\nThe problem asks for the interspecies scaling relationship for the dose normalized by body mass. We can derive this by solving for $D_{\\text{human}}$:\n$$\nD_{\\text{human}} = D_{\\text{dog}} \\times \\frac{W_{\\text{dog}}}{W_{\\text{human}}} \\times \\left( \\frac{W_{\\text{human}}}{W_{\\text{dog}}} \\right)^{0.75}\n$$\nUsing the property of exponents $x^{a} / x^{c} = x^{a-c}$ and $1/x = x^{-1}$:\n$$\nD_{\\text{human}} = D_{\\text{dog}} \\times \\left( \\frac{W_{\\text{dog}}}{W_{\\text{human}}} \\right)^{1} \\left( \\frac{W_{\\text{dog}}}{W_{\\text{human}}} \\right)^{-0.75} = D_{\\text{dog}} \\left( \\frac{W_{\\text{dog}}}{W_{\\text{human}}} \\right)^{1-0.75}\n$$\n$$\nD_{\\text{human}} = D_{\\text{dog}} \\left( \\frac{W_{\\text{dog}}}{W_{\\text{human}}} \\right)^{0.25}\n$$\nThis is the required scaling relationship for converting a dose in mg/kg from one species to another. The dose $D_{\\text{human}}$ calculated this way is the Human-Equivalent Dose (HED).\n\nNow we apply this formula using the given values:\n-   NOAEL in dogs, $D_{\\text{dog}} = 10 \\text{ mg/kg}$\n-   Mean body mass of dogs, $W_{\\text{dog}} = 10 \\text{ kg}$\n-   Representative body mass of humans, $W_{\\text{human}} = 70 \\text{ kg}$\n\nThe HED in mg/kg is:\n$$\n\\text{HED} = 10 \\frac{\\text{mg}}{\\text{kg}} \\times \\left( \\frac{10 \\text{ kg}}{70 \\text{ kg}} \\right)^{0.25}\n$$\nTo determine the proposed starting dose for the clinical trial, the HED is divided by a safety factor ($SF$). The specified safety factor is $SF = 10$:\n$$\n\\text{Starting Dose (mg/kg)} = \\frac{\\text{HED}}{SF} = \\frac{10 \\times \\left( \\frac{10}{70} \\right)^{0.25}}{10} \\frac{\\text{mg}}{\\text{kg}} = \\left( \\frac{10}{70} \\right)^{0.25} \\frac{\\text{mg}}{\\text{kg}}\n$$\nFinally, to find the absolute starting dose for a $70 \\text{ kg}$ adult, we multiply the starting dose per kg by the adult's body mass:\n$$\n\\text{Absolute Starting Dose} = \\text{Starting Dose (mg/kg)} \\times W_{\\text{human}}\n$$\n$$\n\\text{Absolute Starting Dose} = \\left( \\frac{10}{70} \\right)^{0.25} \\frac{\\text{mg}}{\\text{kg}} \\times 70 \\text{ kg}\n$$\nNow, we compute the numerical value and round to three significant figures as requested.\n$$\n\\text{Absolute Starting Dose} = 70 \\times \\left( \\frac{10}{70} \\right)^{0.25} \\text{ mg} \\approx 70 \\times 0.620436 \\text{ mg}\n$$\n$$\n\\text{Absolute Starting Dose} \\approx 43.43052 \\text{ mg}\n$$\nRounding to three significant figures, the absolute starting human dose is $43.4$ mg.",
            "answer": "$$\\boxed{43.4}$$"
        },
        {
            "introduction": "A robust Target Product Profile must precisely define the desired level of efficacy. For therapies affecting time-to-event outcomes, like in oncology, this is often expressed as a target hazard ratio ($HR$). This exercise demonstrates how to translate this relative risk metric into a tangible clinical endpoint—the median time to event—allowing your team to set clear, quantitative, and clinically meaningful goals for the investigational drug .",
            "id": "5006076",
            "problem": "A translational medicine team is drafting a Target Product Profile (TPP) for a first-in-class therapy intended to improve time-to-event outcomes compared with the current standard of care. In the indication under consideration, the standard-of-care arm has a baseline median time to event of $12$ months. The TPP specifies a target hazard ratio $HR$ of $0.70$ for the investigational therapy relative to control. Assuming a proportional hazards framework and an exponential time-to-event model with a constant hazard in each arm, compute the expected median time to event for the investigational arm implied by these TPP targets. Round your answer to four significant figures and express it in months.",
            "solution": "Let $T$ be a random variable representing the time to event. The problem states that $T$ follows an exponential distribution. The survival function, $S(t)$, which is the probability that the event has not occurred by time $t$, is given by:\n$$S(t) = P(T > t) = \\exp(-\\lambda t)$$\nwhere $\\lambda$ is the constant hazard rate.\n\nThe median time to event, denoted by $t_m$, is the time at which the survival probability is $0.5$. We can find the relationship between $t_m$ and $\\lambda$ by setting $S(t_m) = 0.5$:\n$$S(t_m) = \\exp(-\\lambda t_m) = 0.5$$\nTaking the natural logarithm of both sides:\n$$-\\lambda t_m = \\ln(0.5) = \\ln\\left(\\frac{1}{2}\\right) = -\\ln(2)$$\nSolving for $t_m$ gives:\n$$t_m = \\frac{\\ln(2)}{\\lambda}$$\nThis equation establishes a direct relationship between the median time to event and the constant hazard rate for an exponential distribution.\n\nLet the subscripts $C$ and $I$ denote the control and investigational arms, respectively. We have:\n-   Hazard rate for the control arm: $\\lambda_C$\n-   Median time to event for the control arm: $t_{m,C}$\n-   Hazard rate for the investigational arm: $\\lambda_I$\n-   Median time to event for the investigational arm: $t_{m,I}$\n\nFrom the problem statement, we are given $t_{m,C} = 12$ months. Using the derived relationship, we can express the hazard rate for the control arm as:\n$$\\lambda_C = \\frac{\\ln(2)}{t_{m,C}} = \\frac{\\ln(2)}{12}$$\nThe problem assumes a proportional hazards framework, where the hazard ratio, $HR$, is the ratio of the hazard rates and is constant over time:\n$$HR = \\frac{\\lambda_I}{\\lambda_C}$$\nWe are given $HR = 0.70$. We can now solve for the hazard rate of the investigational arm, $\\lambda_I$:\n$$\\lambda_I = HR \\cdot \\lambda_C = 0.70 \\cdot \\frac{\\ln(2)}{12}$$\nOur goal is to compute the median time to event for the investigational arm, $t_{m,I}$. We use the same relationship between median and hazard rate:\n$$t_{m,I} = \\frac{\\ln(2)}{\\lambda_I}$$\nSubstituting the expression for $\\lambda_I$:\n$$t_{m,I} = \\frac{\\ln(2)}{0.70 \\cdot \\frac{\\ln(2)}{12}}$$\nThe $\\ln(2)$ terms cancel out, yielding a simplified expression:\n$$t_{m,I} = \\frac{12}{0.70}$$\nNote that for an exponential model under proportional hazards, the ratio of medians is the reciprocal of the hazard ratio: $t_{m,I} / t_{m,C} = 1 / HR$.\n\nNow we perform the numerical calculation:\n$$t_{m,I} = \\frac{12}{0.70} \\approx 17.142857... \\text{ months}$$\nThe problem requires the answer to be rounded to four significant figures. The first four significant figures are $1$, $7$, $1$, and $4$. The fifth digit is $2$, which is less than $5$, so we round down.\n$$t_{m,I} \\approx 17.14 \\text{ months}$$\nThus, the expected median time to event for the investigational arm is $17.14$ months.",
            "answer": "$$\\boxed{17.14}$$"
        },
        {
            "introduction": "The success of a targeted therapy is often inextricably linked to the performance of a companion diagnostic. This practice delves into the real-world implications of a screening assay's TPP, moving beyond simple sensitivity and specificity to calculate its Positive and Negative Predictive Values ($PPV$ and $NPV$) in a realistic, low-prevalence population . By also considering the impact of biomarker prevalence, you will learn to critically assess the feasibility and cost-effectiveness of a proposed screening strategy.",
            "id": "5006164",
            "problem": "A translational medicine team is drafting a Target Product Profile (TPP) for a noninvasive screening assay intended for primary care use to detect a rare disease in an asymptomatic adult population. The intended use population has disease prevalence $p = 0.01$. The candidate assay has sensitivity $s = 0.90$ and specificity $c = 0.95$ when evaluated against a clinically adjudicated reference standard. The therapy that motivates the screening program is indicated only for patients with a companion biomarker that has population prevalence $b = 0.25$. Assume, for the purpose of interpreting the TPP, that biomarker status is independent of disease status and of assay error.\n\nUsing only standard probability axioms, the definitions of sensitivity, specificity, and prevalence, and Bayes’ theorem, do the following:\n\n1) Derive symbolic expressions for the Positive Predictive Value (PPV) and Negative Predictive Value (NPV) of the assay as functions of $s$, $c$, and $p$.\n\n2) Compute the numerical values of PPV and NPV for $s = 0.90$, $c = 0.95$, and $p = 0.01$. Express both as decimals and round to four significant figures.\n\n3) Briefly interpret, in the context of TPP decision-making for an asymptomatic screening claim, how the computed PPV and NPV interact with the biomarker prevalence $b = 0.25$ when estimating the fraction of initial positive screens that will ultimately be both truly diseased and biomarker-eligible for therapy. Your interpretation should be qualitative, but any computed intermediate quantities should be expressed as decimals or fractions, not as percentages.\n\nReport only the PPV and NPV values as the final numerical answer. No units are required.",
            "solution": "Let us define the following events:\n- $D$: The event that an individual has the disease.\n- $D^c$: The event that an individual does not have the disease.\n- $T^+$: The event that the assay result is positive.\n- $T^-$: The event that the assay result is negative.\n- $B$: The event that an individual has the companion biomarker.\n\nThe givens can be formally expressed as probabilities:\n- Disease prevalence: $P(D) = p = 0.01$. From this, $P(D^c) = 1 - p = 0.99$.\n- Assay sensitivity: $P(T^+ | D) = s = 0.90$.\n- Assay specificity: $P(T^- | D^c) = c = 0.95$.\n- Biomarker prevalence: $P(B) = b = 0.25$.\n\nFrom the definitions of sensitivity and specificity, we can derive the probabilities of the complementary events:\n- False Negative Rate: $P(T^- | D) = 1 - s = 1 - 0.90 = 0.10$.\n- False Positive Rate: $P(T^+ | D^c) = 1 - c = 1 - 0.95 = 0.05$.\n\nThe problem states that biomarker status is independent of disease status and of assay error.\n\n**1) Symbolic Derivations of PPV and NPV**\n\nThe Positive Predictive Value (PPV) is the probability that an individual with a positive test result actually has the disease. This is the conditional probability $P(D | T^+)$.\nUsing Bayes' theorem:\n$$PPV = P(D | T^+) = \\frac{P(T^+ | D) P(D)}{P(T^+)}$$\nThe denominator, $P(T^+)$, is the total probability of a positive test result. It can be expanded using the law of total probability:\n$$P(T^+) = P(T^+ | D) P(D) + P(T^+ | D^c) P(D^c)$$\nSubstituting the symbolic variables for their respective probabilities:\n$$P(T^+) = s \\cdot p + (1 - c) \\cdot (1 - p)$$\nSubstituting this back into the expression for PPV gives the final symbolic form:\n$$PPV = \\frac{s \\cdot p}{s \\cdot p + (1 - c) \\cdot (1 - p)}$$\n\nThe Negative Predictive Value (NPV) is the probability that an individual with a negative test result is truly free of the disease. This is the conditional probability $P(D^c | T^-)$.\nUsing Bayes' theorem:\n$$NPV = P(D^c | T^-) = \\frac{P(T^- | D^c) P(D^c)}{P(T^-)}$$\nThe denominator, $P(T^-)$, is the total probability of a negative test result, expanded using the law of total probability:\n$$P(T^-) = P(T^- | D^c) P(D^c) + P(T^- | D) P(D)$$\nSubstituting the symbolic variables:\n$$P(T^-) = c \\cdot (1 - p) + (1 - s) \\cdot p$$\nSubstituting this back into the expression for NPV gives the final symbolic form:\n$$NPV = \\frac{c \\cdot (1 - p)}{c \\cdot (1 - p) + (1 - s) \\cdot p}$$\n\n**2) Numerical Computation of PPV and NPV**\n\nWe are given $s = 0.90$, $c = 0.95$, and $p = 0.01$.\n\nFor PPV:\n$$PPV = \\frac{0.90 \\cdot 0.01}{0.90 \\cdot 0.01 + (1 - 0.95) \\cdot (1 - 0.01)}$$\n$$PPV = \\frac{0.009}{0.009 + 0.05 \\cdot 0.99}$$\n$$PPV = \\frac{0.009}{0.009 + 0.0495} = \\frac{0.009}{0.0585} \\approx 0.153846...$$\nRounding to four significant figures, $PPV = 0.1538$.\n\nFor NPV:\n$$NPV = \\frac{0.95 \\cdot (1 - 0.01)}{0.95 \\cdot (1 - 0.01) + (1 - 0.90) \\cdot 0.01}$$\n$$NPV = \\frac{0.95 \\cdot 0.99}{0.95 \\cdot 0.99 + 0.10 \\cdot 0.01}$$\n$$NPV = \\frac{0.9405}{0.9405 + 0.001} = \\frac{0.9405}{0.9415} \\approx 0.9989378...$$\nRounding to four significant figures, $NPV = 0.9989$.\n\n**3) Interpretation in the Context of a TPP**\n\nThe fraction of initial positive screens that will ultimately be both truly diseased and biomarker-eligible for therapy corresponds to the conditional probability $P(D \\cap B | T^+)$.\n\nGiven the assumption that biomarker status ($B$) is independent of disease status ($D$) and assay error (represented by the test outcome $T^+$ given disease status), we can simplify the expression. The independence of $B$ from $D$ and assay error implies $P(B | D, T^+) = P(B)$.\n\nWe can write $P(D \\cap B | T^+) = P(D | T^+) P(B | D, T^+)$.\nWith the independence assumption, this simplifies to:\n$$P(D \\cap B | T^+) = P(D | T^+) \\cdot P(B) = PPV \\cdot b$$\nThis quantity represents the \"actionable\" predictive value of a positive test.\n\nUsing the computed PPV and the given biomarker prevalence $b=0.25$:\n$$P(D \\cap B | T^+) = 0.1538 \\times 0.25 = 0.03845$$\n\n**Interpretation for TPP Decision-Making:**\nThe computed PPV of $0.1538$ signifies that for this rare disease, only about $15.4$ out of every $100$ positive screening tests will correspond to a truly diseased individual. The remaining $\\sim 84.6$ are false positives. This low PPV is a known challenge when screening for low-prevalence conditions. The NPV, however, is extremely high ($0.9989$), indicating that a negative result is very effective at ruling out the disease, which is a desirable characteristic for a screening test.\n\nThe biomarker prevalence further constrains the utility of a positive test. The fraction of positive screens that are both truly diseased and eligible for the indicated therapy is only $0.03845$. This means that for approximately every $100$ individuals who receive a positive screening result and undergo subsequent confirmatory testing and biomarker analysis, only about $4$ will ultimately be candidates for the therapy. A TPP must weigh the clinical benefit of identifying these $4$ individuals against the costs, risks, and patient anxiety associated with the $\\sim 96$ individuals who receive an initial positive result but are either not diseased or not biomarker-eligible. For a TPP, this low \"actionable positive\" fraction might be deemed unacceptable, potentially leading to a decision that a higher assay specificity ($c$) is required to reduce the number of false positives, or that the screening program is not feasible without a more targeted screening population or a less burdensome confirmatory pathway.",
            "answer": "$$\\boxed{\\begin{pmatrix} 0.1538 & 0.9989 \\end{pmatrix}}$$"
        }
    ]
}